BPC 157 reduces various arrhythmias (i.e., potassium overdose-induced hyperkalemia (Strinic et al., 2017), bupivacaine (Zivanovic-Posilovic et al., 2016), lidocaine (Lozic et al., 2020), and succinylcholine (Stambolija et al., 2016))
For patients seeking licensed weight management options in the UK, treatments appraised by NICE include semaglutide (Wegovy) for the management of overweight and obesity, and tirzepatide (Mounjaro) for weight management both subject to specific eligibility criteria
This allows clear identification of which compound causes any effects
However, the tissue healing and regenerative signaling it initiates can last significantly longer
Patients experiencing adverse reactions are encouraged to contact their healthcare provider promptly